Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

TYK Medicines

Status and phase: Not yet enrolling; Phase 2; Phase 1

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)

Treatments: Drug: Abiraptor; Drug: TY-302

Study type: Interventional

Funder types: Industry

Identifiers

NCT07104617

TYKM1602301

Details and patient eligibility

About

This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy

Full description

This is an open-label, multi-center, dose-escalation and expansion phase Ib/II study to evaluate dose limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) in subjects with metastatic castration-resistant prostate cancer (mCRPC).

To evaluate the efficacy of TY-302 combined with Abiraterone tablets in subjects with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy

Enrollment: 48 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18 years.

2. Metastatic castration-resistant prostate adenocarcinoma confirmed by pathology (with no neuroendocrine or small cell features indicated by the initial pathological examination), if pathological examination is performed in the subsequent CRPC stage, the accompanying other pathological types should not exceed 10%. Those with only pelvic lymph node metastasis or local recurrent metastasis (such as in the bladder, rectum, etc.) cannot be included.

3. Testosterone levels ≤50ng/dL (≤1.75nmol/L) within 28 days prior to the first administration. If the patient has not undergone bilateral orchiectomy in the past, they must be undergoing and voluntarily continue to receive LHRH agonists/antagonists for androgen deprivation therapy throughout the study treatment period

4. During screening, if the disease progresses, that is, the subject experiences one or more of the following three conditions; PSA progression is defined as no PSA > 1ng/ml and at least two elevated PSA levels with an interval of ≥1 week. ② Disease progression as defined in RECIST 1.1; ③ Bone disease progression as defined by the PCWG3 standard refers to the discovery of ≥2 new lesions on bone scans.

5. Previous anti-tumor treatment must meet the following requirements: having failed in only one approved and marketed novel endocrine therapy in the past (referring to disease progression during the process of novel endocrine therapy; The definition of disease progression is the same as that of inclusion criterion 4), such as enzalutamide, apatamide, darotamide or rivelutamide, etc., and no previous treatment with abiraterone acetate has been received.

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and life expectancy > 3 months.

7. Have good organ functions, including:

   Liver function: Total bilirubin (TBIL) ≤ 1.5×ULN (except for documented Gilbert syndrome), alanine aminotransferase (ALT) ≤ 2.5×ULN, and aspartate aminotransferase (AST) ≤ 2.5×ULN (for patients with liver metastasis, ALT/AST≤5×ULN), albumin ≥3.0g/L; Renal function: Serum creatinine (Cr) ≤ 1.5×ULN, or creatinine clearance rate ≥50 mL/min (calculated according to the Cockcroft and Gault formula); Blood routine: PLT ≥ 100×109/L, ANC ≥ 1.5×109/L, WBC≥ 3.5×109/L and Hb ≥ 90g/L; The international normalized ratio (INR) is ≤1.5, and the activated partial prothrombin time (APTT) is ≤1.5×ULN (in the absence of anticoagulation therapy).

8. agrees to maintain abstinence (control heterosexual sexual intercourse) or take contraceptive measures, and agrees not to donate sperm

9. Be able to provide written informed consent approved by institutional review board (IRB) or independent ethics committee (IEC).

Exclusion criteria

1. Patients with the following treatment:

   1. Received CDK4/6 inhibitors (e.g., Palbociclib, Ribociclib, Abemaciclib, Trilaciclib/G1T38, SHR6390, pirociclib) ;
   2. Received abirone acetate tablets and their analogues (CYP17 inhibitors, such as ketoconazole, etc.) or two or more novel endocrine therapies for prostate cancer;
   3. Received with strontium-89, samarium or radium-223 within 12 weeks prior to the first administration;
   4. Received systemic treatment for prostate cancer (anti-androgen therapy, chemotherapy, targeted therapy, immunotherapy, or other interventional clinical trial drugs, except castration therapy drugs) within 4 weeks prior to the first medication;
   5. Received traditional Chinese medicine preparations with anti-tumor therapeutic effects within one week before the first administration, or those who have received nitrourea or mitomycin treatment within six weeks before the first administration;
   6. Received blood transfusion, albumin infusion or used hematopoietic growth factor within 2 weeks before the first administration;
   7. Within two weeks prior to the first administration, the patient has received treatment with drugs prohibited by the protocol [such as CYP3A strong suppressors, CYP3A strong inducers, and CYP3A-sensitive substrates with a narrow therapeutic index, etc.];
   8. Major surgery was performed within 28 days before the first administration of the drug , or surgery was performed when the surgical effect had not yet recovered at the time of screening or during the planned enrollment for treatment;
   9. Has received allogeneic transplants such as stem cell transplantation, bone marrow transplantation or liver transplantation in the past;
   10. Palliative radiotherapy was received within 2 weeks before the first administration;
   11. The first administration was within no more than five half-lives from the implantation of radioactive particles.

2. In addition to prostate cancer, there are other malignant tumors at the same time (excluding basal cell carcinoma or squamous cell carcinoma of the skin that can be treated locally and have been cured, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma of the breast and papillary thyroid carcinoma, etc.); Excluding other malignant tumors that have been cured by radical treatment for at least 5 years;

3. There is previous evidence indicating the existence of homologous recombination gene mutations (such as BRCA1, BRCA2, etc.)

4. Known to be allergic to any excipients of TY-302 Capsules, or to Abiraterone acetate tablets and their excipients;

5. There are contraindications for the use of prednisone (corticosteroid), such as active infection, active peptic ulcer, recent gastrointestinal anastomosis surgery, fracture, wound healing period, corneal ulcer, severe osteoporosis or other conditions. Or there may be diseases that require treatment with systemic steroid hormones (i.e., other corticosteroids at a physiological dose of more than 10mg/ day, such as prednisone or similar drugs);

6. Patients whose progression of bone and soft tissue lesions cannot be evaluated, that is, those who meet both of the following criteria simultaneously:

   1. The bone scan showed a super bone imaging;
   2. According to RECIST1.1 criteria, there were no assessable soft tissue lesions (measurable or unmeasurable).

7. The patient has any unstable or other disease or medical condition that may affect its safety or compliance with the study, any serious or uncontrolled systemic disease, including uncontrolled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥95 mmHg), uncontrolled diabetes, active bleeding, ocular lesions Other serious diseases of the mental, nervous and other systems;

8. Clinically obvious digestive tract abnormalities during screening may affect drug intake, transport or absorption (such as dysphagia, uncontrollable nausea and vomiting, ulcerative colitis, Crohn's disease, chronic diarrhea, intestinal obstruction, etc.);

9. Severe bone injury caused by tumor bone metastasis, with pathological fractures of important parts or spinal cord compression expected to occur in the near future within 6 months prior to knowledge;

10. There is cancerous meningitis or untreated central nervous system metastasis. Those who have previously received systemic or radical treatment for brain metastases (radiotherapy or surgery), and whose stability has been maintained for at least one month as confirmed by imaging, and who have stopped systemic hormone therapy (with a dose greater than 10mg/ day prednisone or other equivalent dose hormones) for more than two weeks and have no clinical symptoms, can be included;

11. Patients with clinically symptomatic third space effusion (such as pleural effusion, ascites, pericardial effusion) who require puncture and drainage, or those who have received puncture and drainage within 2 weeks before randomization or the first medication;

12. At the time of screening, the toxicity of previous treatments had not yet recovered. According to CTCAE v5.0, there were still grade ≥2 AES (excluding special toxicities such as alopecia, fatigue, increased GGT, and increased ALP);

13. Have severe cardiovascular diseases, including but not limited to:

    1. At rest, a 12-lead electrocardiogram (ECG) examination showed that the QTcF was ≥470ms;
    2. There are severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, etc;
    3. Acute coronary syndrome, congestive heart failure (New York Heart Association (NYHA)) cardiac function grade ≥2, aortic dissection or other grade 3 cardiovascular events occurred within 6 months before the first administration;
    4. Left ventricular ejection fraction (LVEF) <50%;

14. There is a history of thromboembolism or cerebrovascular events within 6 months before the first administration, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis or pulmonary embolism, etc;

15. There was evidence of radiation pneumonitis, interstitial lung disease or interstitial pneumonia (ILD) requiring hormone therapy during the screening period, or drug-induced ILD, or any active ILD (such as acute exacerbation or progressive pneumonia/pulmonary fibrosis at baseline). Or pulmonary symptoms that the researchers consider unsuitable for enrollment, or high-risk factors that make it unsuitable for enrollment due to the possibility of interstitial lung disease;

16. There was a severe infection within 4 weeks before the first administration, including but not limited to bacteremia requiring hospitalization and severe pneumonia; There was an active infection of CTCAE grade ≥2 that required systemic antibiotic treatment within 2 weeks before the first administration (except for local chronic infections or prophylactic antibiotic use that the investigator determined did not require treatment);

17. Those with a history of active pulmonary tuberculosis infection within 6 months prior to the first administration;

18. People infected with active human immunodeficiency virus (HIV), syphilis, hepatitis C virus (HCV) or hepatitis B virus (HBV). Active HBV, HCV and HIV infections are defined as:

    1. positive HBsAg and HBV DNA ≥500cps/ml/HBV DNA ≥1000u/ml;
    2. Anti-hcv antibody and HCV RNA positive;
    3. HIV antibody positive.

19. Known history of alcohol or drug abuse or dependence; Mental disorder; Or the researcher believes that there is a history of other serious systemic diseases or other reasons that make the participants unsuitable for this study (such as not meeting the most beneficial treatment for the subjects, subject compliance, etc.).

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

48 participants in 1 patient group

TY-302+Abiraptor

Experimental group

Description:

Find the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D) of TY-302, given orally. • Increased dose cohorts from low dose to MTD, starting at 75mg Once a day. Abiraterone, 1000mg each time, once a day.

Treatment:

Drug: TY-302

Drug: Abiraptor